Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World... Here's What It Was Like

Why does it matter? Because the most powerful psychedelic on earth just outperformed five years of elite longevity science

Bryan Johnson walked out of a 5-MeO-DMT session 48 hours ago — nine milligrams intramuscular, eighteen vaporized — and is still figuring out how to talk about it. What he can say: a single session reset him more completely than everything in his five-year longevity stack, combined. He has the brain scans, blood biomarkers, EEG, and real-time fMRI to test that claim.

• 5-MeO-DMT didn't soften the default mode network — it annihilated it, producing measurable childlike behavioral states two days later • Psilocybin moved his blood glucose from the 99.5th to the 99.9th percentile — a whole-body metabolic reset no drug had touched at that baseline • VCs are writing anti-psychedelic clauses into founder deal docs — a contractual response to documented founder abandonment post-experience • Bryan is now testing molecules on lab-grown versions of his own heart, liver, and lungs before putting them in his body

One session of 5-MeO-DMT outperformed five years of Bryan Johnson's longevity stack — combined

Nine milligrams intramuscular, eighteen vaporized. Within ten seconds, Bryan Johnson was gone.

What came back, 48 hours later, felt categorically different from anything his protocols had produced. "If I just subjectively compare my experience with 5 MO to you having a better diet and exercising every day and sleeping well and doing the sauna and doing hyper oxygen therapy — this was more efficacious than all of them in terms of the reset of me as a human."

For someone who has spent five years working through every evidence-backed longevity intervention — rapamycin, metformin, hyperbaric oxygen, precision nutrition, sleep optimization — that's a remarkable thing to say. He's not dismissing those. He's saying 5-MeO-DMT operated in a different category. "Nothing like what 5 MO did in terms of the reset of me as a human."

The experience resists description. He calls it raw consciousness meeting raw intelligence — take whatever those words conjure, multiply by a thousand, extend infinitely in every dimension. The critical moment came fast: panic or surrender. Either you wrestle it until it ends, or you release all attachment, all preconditions, all ego and control. When he surrendered, it opened into what he describes as the most dynamic experience of his life — beyond marriage, children, major accomplishments. "I just can't imagine anything more miraculous."

5-MeO-DMT doesn't soften the default mode network — it annihilates it, and the proof showed up 48 hours later

Two days after the session, Bryan woke up laughing in a dream — something he'd never done before, couldn't recall ever doing. He looked it up: it's a characteristic of children.

The default mode network is the neural rumination engine — the voice that asks "how do I feel, what should I be doing, did I screw that up?" Children don't run this loop. Adults calcify it into rigid ruts over decades. "As you age, your experience of reality becomes increasingly narrow."

Psilocybin dampens the DMN. Bryan had brain imaging from Kernel — an optical neural interface — showing the rewired connectivity after psilocybin: old hub-to-hub traffic patterns quieted, new connections emergent. Picture the brain as a globe with airports; psilocybin scrambles the flight routes. 5-MeO-DMT didn't scramble them. It blasted the entire map clean. "5-MeO-DMT compared to psilocybin — just absolutely blasted clean my default mode network. It felt like psilocybin dampens it, softens it, but this thing just annihilated my default."

The behavioral readout arrived before any lab results. The day after, when his partner Kate got upset with him, something was different. No urge to escalate, defend, package the grievance, weaponize it later. They had it out, and it was done — like children after a fight. Laughing in dreams, frictionless conflict resolution two days post-session: these aren't metaphors for feeling better. They're objective behavioral markers that something neurologically real happened.

Psilocybin produced a first-in-human observation: a whole-body metabolic reset that moved blood glucose from the 99.5th to the 99.9th percentile

25 milligrams of psilocybin, three doses, the world's most quantified experiment of its kind. What the blood work showed afterward was something Bryan's team hadn't predicted.

His blood glucose before was already in the top 99.5th percentile of the general population. After psilocybin, it shifted to the top 99.9th percentile. "To move my blood glucose from that level is very, very hard." This wasn't a drug targeting glucose pathways — metformin does that. This was something upstream. "Not like metformin where you're doing something on blood glucose — this just had a reset across the body." His microbiome changed. Brain imaging showed dramatic restoration of youthful connectivity patterns.

The mechanism is completely unlike anything in the metabolic drug playbook. Psilocybin apparently touched inflammation, gut microbiome, blood glucose, and neural connectivity simultaneously — a systemic effect, not a neurological one with metabolic spillover. Researchers focused only on the mental health indications are missing a signal worth taking seriously.

This is what pointed Bryan toward 5-MeO-DMT. If psilocybin did that, what happens when you apply five to ten times the potency?

Every organ has bent to Bryan's longevity protocols — except the brain, which has resisted everything, until now

Heart, lungs, muscle, body fat — Bryan's team has successfully rejuvenated all of it. The brain has resisted every intervention.

This isn't a gap in ambition. It's a structural problem. Gene therapies and cell therapies can't safely target neurons yet. "If you grow the neurons back maybe in the wrong way — like we don't know." Neuroregeneration via Yamanaka factors carries cancer risk that tissue repair doesn't; a mistake in the brain doesn't get corrected the way a mistake in muscle can.

Psychedelics sidestep the problem entirely. They don't grow neurons back — they reorganize the existing network. Reset the patterns, restore the openness, without touching the hardware. "Maybe that's the role of psychedelics — you just get a wash of like the snapback of like I can, and I can bounce."

For a field that has solved most of the body, the brain remains the hardest problem. Psychedelics are currently the leading candidate.

VCs are putting anti-psychedelic clauses in founder deal docs — and it's not anxiety, it's documented pattern recognition

One investor already put it in writing: take our money, don't touch psychedelics for the life of the company.

"I've seen so many examples where people put money in, then you lose the founder. Like they're off, everyone's high and dry." The failure mode is specific and recurring: founder does a heavy psychedelic experience, values shift, company gets abandoned. Investors, employees, families left exposed.

The philosophical weight here is real and uncomfortable. "Your values can change, too. You could judge values ascribed to you by a religion or perhaps values ascribed to you by responsibility to family members, children, spouses, partners. You abandon them." Post-experience rewiring isn't always toward something better — it's toward something different. Whether that's growth or destruction is unpredictable from the outside.

Bryan came back more motivated. But he's unusual — surrounded by people who encourage frontier play, with no obligations pulling him toward a prior identity. Most people doing this aren't in that position, and most are doing it in unstructured, unquantified settings with no professional oversight. That's a fundamentally different risk profile.

In an AI-accelerated world, the mental rigidity psychedelics break may be more dangerous than the value shifts they cause

The standard risk framing flips when you accelerate the timeline.

AI is the dominant engine of innovation now, and it's moving faster than adults can update their mental models. "Can humans change fast enough in the world where AI is the dominant engine of innovation?" If rigidity — not intelligence — is the bottleneck, the adult tendency toward cognitive rut-formation becomes the liability. "There's potentially where it flips from a liability to an asset where now I do want that restructure changing, even though you have some tail risk of like maybe my priorities will shift."

The next wave of demand for psychedelics may not come from therapy seekers. It may come from high-functioning professionals who need to update their priors as fast as the world is actually changing.

Before Bryan puts anything new in his body, it goes through Bryan Johnson first — a lab-dish version grown from his own stem cells

The organoid project is already operational. Bryan's team took his cells, converted them to induced pluripotent stem cells via Yamanaka factors, then differentiated them into heart, liver, and lung tissue. A Bryan Johnson organ sits in a dish, ready to receive experimental molecules.

The advantage is time compression. Instead of putting a compound in his body and waiting months to see what happens, he runs the experiment in-dish first. "Now you get the advantage of time of acceleration of like what to take, why, what dose." First in-dish tests haven't happened yet — but the infrastructure exists. Pair that with AI-assisted analysis, and years of trial-and-error longevity experimentation start to look like months.

The quantified data being built right now could move psychedelics from an anecdote category into clinical longevity science

What separates Bryan's experiment from fifty years of prior psychedelic claims is measurement infrastructure: Kernel optical brain interfaces, fMRI, EEG, blood biomarkers, microbiome sequencing. No one has pointed this level of rigor at a 5-MeO-DMT session before.

If the brain scan results match the behavioral markers Bryan is already reporting, the question stops being whether to take this seriously and starts being how fast to run trials.

The molecule that fits in a vaporizer might be the most important longevity intervention nobody's funding yet.

---

Topics: psychedelics, longevity, biohacking, 5-MeO-DMT, psilocybin, default mode network, neuroplasticity, gene therapy, organoids, stem cells, mitochondria, AI adaptation, venture capital, brain rejuvenation, Bryan Johnson